RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Verastem Inc. (NASDAQ: VSTM ) is one of the 10 best stocks under $10 that could triple .

On July 7, RBC Capital maintained its Outperform rating on Verastem Inc. (NASDAQ:VSTM). The firm reduced the target price from $15 to $14, which still offers a revised upside potential of over 211%. The price target adjustment accompanies the firm's broader biotech sector earnings preview for the second quarter.

RBC Capital highlighted the sector's notable momentum during June, including a 2-week rally outpacing the S&P. This was supported by encouraging data around innovations, as well as a favorable sentiment regarding the FDA's flexible stance.

The firm expects capital inflows to persist as the sector's outlook offers more visibility compared to others. It acknowledged strong second quarter earnings across the sector, with more opportunities to achieve earnings beats, and maintains that the ongoing M&A activity is likely to offer more support.

Back on June 23, Verastem Inc. (NASDAQ:VSTM) revealed encouraging preliminary results from the company's Phase 1/2 trial for the TARGET-D 101 study of VS-7375. It is an investigational oral inhibitor that targets KRAS G12D in patients with late-stage KRAS G12D-mutated tumors.

Results indicated promising clinical activity with a sound tolerability and safety profile across several tumor types and dosage levels. The tumors include advanced non-small cell lung cancer, metastatic colorectal cancer, and metastatic pancreatic ductal carcinoma.

Verastem Inc. (NASDAQ:VSTM) is a development-stage biopharmaceutical company involved in developing and commercializing drugs for the treatment of cancer. Its product candidates are Avutometinib, FAKZYNJA, Defactinib, VS-7375, CO-PACK, and AVMAPKI. The company is involved in clinical studies of RAMP 301, RAMP 205, FRAME, VS-7375-101, RAMP 203, and RAMP 201.

While we acknowledge the risk and potential of VSTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VSTM and that has 10,000% upside potential, check out our report about this cheapest AI stock .

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years .

Sinergia Empresarial continuará el seguimiento de esta información sobre rBC Capital Reaffirms Outperform Rating For Verastem (VSTM) y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.